Formulation and Evaluation of Orodispersible Tablets of Naproxen Sodium and Ondansetron HCl for Migraine: A Review

Raj Nandani; Arti Kori; Shivanand Patil

doi:10.52711/2231-5713.2026.00055

Asian Journal of Pharmacy and Technology

ISSN

2231-5713 (Online)
2231-5705 (Print)

Submit Article

Formulation and Evaluation of Orodispersible Tablets of Naproxen Sodium and Ondansetron HCl for Migraine: A Review

Author(s): Raj Nandani, Arti Kori, Shivanand Patil

Email(s): Email ID Not Available

DOI: 10.52711/2231-5713.2026.00055

Address: Raj Nandani, Arti Kori, Shivanand Patil
Shree Dev Bhoomi Institute of Education Sciences and Technology, Dehradun, Uttrakhand, India.
*Corresponding Author

Published In: Volume - 16, Issue - 4, Year - 2026

View HTML

Purchase PDF

ABSTRACT:
Migraine is a chronic neurological disorder characterized by recurrent episodes of severe headache associated with nausea, vomiting, photophobia, and phonophobia. Conventional oral dosage forms often fail to provide rapid therapeutic relief because delayed gastric emptying during migraine attacks reduces drug absorption. Orodispersible tablets (ODTs) rapidly disintegrate in the oral cavity without the need for water, providing faster drug release, improved bioavailability, and better patient compliance. The present review discusses the formulation and evaluation of ODTs containing Naproxen Sodium and Ondansetron HCl for migraine management. Naproxen Sodium provides analgesic and anti-inflammatory action, whereas Ondansetron HCl effectively controls nausea and vomiting. Their combination in an ODT offers rapid symptom relief, enhanced therapeutic efficacy, and improved patient convenience. The review also highlights formulation approaches, evaluation parameters, advantages, limitations, recent technological developments, and future prospects of ODTs in migraine therapy. Overall, ODTs represent an effective and patient-friendly drug delivery system for improving migraine treatment outcomes.

Keywords:

Cite this article:
Raj Nandani, Arti Kori, Shivanand Patil. Formulation and Evaluation of Orodispersible Tablets of Naproxen Sodium and Ondansetron HCl for Migraine: A Review . Asian Journal of Pharmacy and Technology. 2026; 16(4):395-1. doi: 10.52711/2231-5713.2026.00055

Cite(Electronic):
Raj Nandani, Arti Kori, Shivanand Patil. Formulation and Evaluation of Orodispersible Tablets of Naproxen Sodium and Ondansetron HCl for Migraine: A Review . Asian Journal of Pharmacy and Technology. 2026; 16(4):395-1. doi: 10.52711/2231-5713.2026.00055 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-4-10

15. REFERENCES:
1. World Health Organization. Headache disorders. Geneva: WHO; 2020.
2. Wilcha RJ, et al. Advances in migraine management. J Neurol. 2024.
3. Sharma J, et al. Orodispersible drug delivery systems in migraine therapy. Int J Pharm Sci. 2025.
4. Aulton ME, Taylor K. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 6th ed. Elsevier; 2021.
5. Talai A, et al. Role of antiemetics in migraine treatment. Neurol Rev. 2020.
6. Gupta MM, Patel MG. Development of Naproxen Sodium ODTs. Int J Pharm Sci. 2023; 15(2): 123-130.
7. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Lippincott Williams & Wilkins; 2020.
8. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad: IPC; 2018.
9. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Elsevier; 2020.
10. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018.
11. Patel R, Mehta S. Fast dissolving drug delivery systems: Recent advances. Asian J Pharm Sci. 2022; 17(1): 12–25.
12. Verma P, Singh SK. Orodispersible tablets: Technologies and evaluation. Int J Drug Dev Res. 2021; 13(4): 89–98.
13. Gupta MM, Patel MG. Development of Naproxen sodium orodispersible tablets for migraine management. Int J Pharm Sci. 2023; 15(2): 123–130.
14. Kumar S, Gupta SK. Evaluation parameters of orodispersible tablets: A comprehensive review. Int J Pharm Sci Rev Res. 2023; 82(1): 45–52.
15. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2020.
16. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019.
17. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018.
18. Katzung BG. Basic and Clinical Pharmacology. 14th ed. New York: McGraw-Hill; 2018.
19. Gupta MM, Patel MG. Development of Naproxen sodium orodispersible tablets for migraine management. Int J Pharm Sci. 2023; 15(2): 123–130.
20. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Elsevier; 2020.
21. Shah P, Patel J. Ondansetron hydrochloride fast dissolving tablets: Formulation and evaluation. J Drug Deliv Sci Technol. 2022; 67: 102987.
22. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2020.
23. Singh R, Sharma PK. Combination therapy in migraine management: Current perspectives. Int J Pharm Sci Rev Res. 2021; 68(1): 120–128.
24. Silberstein SD. Practice guideline update: Acute treatment of migraine in adults. Neurology. 2019; 93(11): 487–499.
25. Dodick DW. Migraine: Current understanding and treatment strategies. N Engl J Med. 2021; 384(2): 158–169.
26. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
27. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 6th ed. Elsevier; 2021.
28. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2020.
29. Patel RP, Baria AH. Orodispersible tablets: Recent advances in formulation technologies. Asian J Pharm Sci. 2022; 17(4): 450–462.
30. Gupta MM, Patel MG. Formulation and evaluation of Naproxen Sodium and Ondansetron Hydrochloride orodispersible tablets for migraine management. Int J Pharm Sci. 2023; 15(2): 123–130.
31. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2020.
32. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 6th ed. Elsevier; 2021.
33. Patel RP, Baria AH. Orodispersible tablets: Technologies and patient compliance. Asian J Pharm Sci. 2022; 17(4): 450–462.
34. Kumar S, Gupta SK. Advances in orodispersible drug delivery systems. Int J Pharm Sci Rev Res. 2023; 82(1): 45–52.
35. Verma P, Singh SK. Orodispersible tablets: Current perspectives and future scope. Int J Drug Dev Res. 2021; 13(4): 89–98.
36. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad: IPC; 2022.
37. Sharma J, Gupta M. Recent advances in oral fast-disintegrating drug delivery systems. J Pharm Innov. 2023; 18(2): 210–223.
38. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 6th ed. Elsevier; 2021.
39. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2020.
40. Patel RP, Baria AH. Challenges in the formulation of orodispersible tablets. Asian J Pharm Sci. 2022; 17(4): 450–462.
41. Kumar S, Gupta SK. Taste masking technologies for orally disintegrating tablets. Int J Pharm Sci Rev Res. 2023; 82(1): 45–52.
42. Verma P, Singh SK. Manufacturing considerations for orodispersible tablets. Int J Drug Dev Res. 2021; 13(4): 89–98.
43. Sharma J, Gupta M. Limitations of oral fast-disintegrating drug delivery systems. J Pharm Innov. 2023; 18(2): 210–223.
44. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad: IPC; 2022.
45. Aulton ME, Taylor KMG. Aulton's Pharmaceutics. 6th ed. Elsevier; 2021.
46. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Lippincott Williams & Wilkins; 2020.
47. Patel RP, Baria AH. Orodispersible tablets: Formulation technologies. Asian J Pharm Sci. 2022; 17(4): 450–462.
48. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad: IPC; 2022.
49. Kumar S, Gupta SK. Evaluation of orodispersible tablets. Int J Pharm Sci Rev Res. 2023; 82(1): 45–52.
50. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Lippincott Williams & Wilkins; 2020.
51. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018.
52. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Elsevier; 2020.
53. Sharma J, Gupta M. Advances in oral fast-disintegrating drug delivery systems. J Pharm Innov. 2023; 18(2): 210–223.
54. Aulton ME, Taylor KMG. Aulton's Pharmaceutics. 6th ed. Elsevier; 2021.
55. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Lippincott Williams & Wilkins; 2020.
56. Patel RP, Baria AH. Challenges in orodispersible tablet formulation. Asian J Pharm Sci. 2022; 17(4): 450–462.
57. Sharma J, Gupta M. Advances in oral fast-disintegrating drug delivery systems. J Pharm Innov. 2023; 18(2): 210–223.
58. Kumar S, Gupta SK. Future trends in orodispersible drug delivery. Int J Pharm Sci Rev Res. 2023; 82(1): 45–52.
59. Allen LV. Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Lippincott Williams & Wilkins; 2020.
60. Aulton ME, Taylor KMG. Aulton's Pharmaceutics. 6th ed. Elsevier; 2021.
61. Verma P, Singh SK. Recent advances in orally disintegrating tablets. Int J Drug Dev Res. 2021; 13(4): 89–98.
62. Patel RP, Baria AH. Emerging technologies in ODT development. Asian J Pharm Sci. 2022; 17(4): 450–462.
63. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018.
64. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Elsevier; 2020.
65. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad: IPC; 2022.

Asian Journal of Pharmacy and Technology (AJPTech.) is an international, peer-reviewed journal, devoted to pharmaceutical sciences...... Read more >>>

RNI: Not Available
DOI: 10.5958/2231–5713